Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
October 28, 2021 16:01 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting
October 27, 2021 07:30 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit
September 14, 2021 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference
September 08, 2021 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
August 18, 2021 07:30 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update
August 12, 2021 07:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index
June 24, 2021 07:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered...
Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer
June 15, 2021 07:00 ET
|
Werewolf Therapeutics, Inc.
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE...
Werewolf Therapeutics Reports First Quarter 2021 Financial Results
June 10, 2021 07:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021
May 27, 2021 07:30 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...